Furthermore, our future studies will focus on the highly heterogeneous microenvironment and explore the spatial distribution of the expression of CD8, FOXP3, PD-1, PD-L1, and other immune checkpoints to better stratify patients and guide clinical immunotherapy for NSCLC patients. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.